ROIV · XBRL financial data

Roivant Sciences financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ROIV's year ends in late March)

In millions of dollars	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2023Mar 31, 2024	FY 2024Mar 31, 2025	FY 2025Mar 31, 2026
Revenue from contracts with customers	55	61	125	29	8
Research and development	483	525	502	550	682
Selling, general and administrative	775	601	687	—	—
General and administrative	775	383	416	591	610
Total operating expenses	1,407	1,237	1,231	1,143	1,294
Operating income (loss)	(1,352)	(1,175)	4,242	(1,003)	(515)
Interest income	—	—	146	258	178
Interest expense	7	28	35	—	—
Other income (expense)	(3)	16	(6)	(11)	4
Income tax expense (benefit)	0	5	22	48	133
Net income (loss)	(845)	(1,009)	4,349	(172)	(300)
Earnings per share, basic USD per share	(1.26)	(1.42)	5.55	(0.24)	(0.43)
Earnings per share, diluted USD per share	(1.26)	(1.42)	5.23	(0.24)	(0.54)
Weighted average shares, basic millions of shares	670	713	783	725	694
Weighted average shares, diluted millions of shares	670	713	831	725	694

Fiscal years (ROIV's year ends in late March)

In millions of dollars	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2023Mar 31, 2024	FY 2024Mar 31, 2025	FY 2025Mar 31, 2026
Cash and cash equivalents	2,060	1,677	6,536	2,715	1,419
Marketable securities	—	—	0	2,171	2,873
Inventory	0	3	35	—	—
Total current assets	2,147	1,799	6,732	5,000	5,167
Property and equipment, net	26	39	19	12	12
Right-of-use asset	61	53	47	89	80
Total assets	2,585	2,390	7,222	5,437	5,709
Accounts payable	35	38	53	24	18
Accrued liabilities	128	167	176	114	206
Current portion of long-term debt	0	41	12	—	—
Total current liabilities	184	272	267	149	281
Long-term debt	210	—	—	—	—
Lease liability, non-current	62	53	47	90	96
Total liabilities	524	782	774	250	416
Retained earnings (accumulated deficit)	(2,764)	(3,773)	576	116	(502)
Total stockholders' equity	1,657	1,158	5,969	4,688	4,527
Total liabilities and equity	2,585	2,390	7,222	5,437	5,709
Common shares outstanding (cover page) millions of shares	701	767	739	680	719

Fiscal years (ROIV's year ends in late March)

In millions of dollars	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2023Mar 31, 2024	FY 2024Mar 31, 2025	FY 2025Mar 31, 2026
Net income (loss)	(845)	(1,009)	4,349	(172)	(300)
Stock-based compensation	565	218	200	289	346
Depreciation and amortization	6	19	22	14	3
Net cash from operating activities	(678)	(843)	(765)	(839)	(750)
Purchases of property and equipment	17	13	1	5	8
Net cash from investing activities	303	(44)	5,204	(1,766)	(682)
Proceeds from issuing common stock	0	312	200	0	0
Share repurchases	—	0	0	1,293	—
Net cash from financing activities	307	499	419	(1,220)	134
Net change in cash	(68)	(382)	4,858	(3,825)	(1,295)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
United Therapeutics	1,189	833	not reported	42.6M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.